SCHEMBL4826581

SCHEMBL4826581

CNCc1cc(F)cc(F)n1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 3/20 0.33
NOS1 P29475 3/20 0.33
LMNA P02545 1/20 0.33
GAA P10253 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPK13 O15264 1/20 0.32
CSNK1D P48730 1/20 0.32
CSNK1E P49674 1/20 0.32
MAPK12 P53778 1/20 0.32
KCNH2 Q12809 1/20 0.32
MAPK11 Q15759 1/20 0.32
MAPK14 Q16539 1/20 0.32
KDM4E B2RXH2 1/20 0.32
TP53 P04637 1/20 0.32
ALK Q9UM73 1/20 0.31
HTR2A P28223 6/20 0.31
SLC6A4 P31645 6/20 0.31
HTR2C P28335 5/20 0.31
PARP1 P09874 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4826754 0.80 KDM4E (0.40) KCNH2KDM4ETP53HTR2ASLC6A4
SCHEMBL4837374 0.80 KDM4E (0.37) NOS3NOS1MAPK13CSNK1DCSNK1E
SCHEMBL4832258 0.71 KDM4E (0.39) NOS3NOS1LMNAGAAL3MBTL1
SCHEMBL12536038 0.71 NPSR1 (0.41) LMNAKDM4ETP53
SCHEMBL1161680 0.68
SCHEMBL3637748 0.67 L3MBTL1 (0.43) L3MBTL1MAPK13CSNK1DCSNK1EMAPK12
SCHEMBL12065872 0.67 KDM4E (0.34) KDM4ETP53
SCHEMBL14088944 0.67 NOS3 (0.41) NOS3LMNAGAAL3MBTL1KDM4E
SCHEMBL3350251 0.66 KDM4E (0.42) NOS3NOS1KDM4EHTR2ASLC6A4
SCHEMBL4835923 0.64 KDM4E (0.33) LMNAGAAL3MBTL1KCNH2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442692-B2 Indanyl-piperazine compounds LES LABORATOIRES SERVIER (FR) 2008-10-28 US disclosed
EP-1707564-B1 Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2007-09-12 EP disclosed
US-20060223830-A1 Indanyl-piperazine compounds LES LABORATOIRES SERVIER (FR) 2006-10-05 US disclosed
EP-1707564-A2 Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2006-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223830-A1 Indanyl-piperazine compounds HTR4, NR4A1, NR4A3 NOS3 845/4885NOS1 1530/4885LMNA 3871/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.